TY - JOUR
T1 - Advances in Combining Radiation and Immunotherapy in Breast Cancer
AU - Nguyen, Anthony T.
AU - Shiao, Stephen L.
AU - McArthur, Heather L.
N1 - Funding Information:
The review described was supported in part by Cedars-Sinai Cancer, which had no role in the preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication. HLM reports grants and personal fees from Bristol-Myers Squibb, Merck, AstraZeneca, and MedImmune; personal fees from Daiichi-Sankyo, Eli Lilly and Company, Pfizer, Genentech, Immunomedics, Puma Biotech, Amgen, Seattle Genetics, Genomic Health, and Spectrum Pharmaceuticals outside the submitted work.
Publisher Copyright:
© 2021 The Authors
PY - 2021/4
Y1 - 2021/4
N2 - Breast irradiation has long been utilized in the adjuvant or metastatic setting to eliminate microscopic disease or to palliate existing disease, respectively. However, preclinical data have demonstrated that radiation can also alter the tumor microenvironment and induce antitumor immune responses. As a result, multiple clinical studies have been undertaken and have reported synergy between radiation and immune checkpoint blockade across various cancer types. Given recent clinical successes with immune checkpoint blockade in both early-stage and metastatic breast cancer, there has been substantial interest in combining radiation and immunotherapy to enhance local and systemic immune responses. Herein, we review the preclinical rationale for combining radiotherapy and immunotherapy, the early clinical trials that have adopted this strategy in breast cancer, and the landscape of ongoing relevant clinical trials. Finally, we propose future directions based on promising preclinical studies that integrate radiation, checkpoint blockade, and novel agents for the treatment of breast cancer.
AB - Breast irradiation has long been utilized in the adjuvant or metastatic setting to eliminate microscopic disease or to palliate existing disease, respectively. However, preclinical data have demonstrated that radiation can also alter the tumor microenvironment and induce antitumor immune responses. As a result, multiple clinical studies have been undertaken and have reported synergy between radiation and immune checkpoint blockade across various cancer types. Given recent clinical successes with immune checkpoint blockade in both early-stage and metastatic breast cancer, there has been substantial interest in combining radiation and immunotherapy to enhance local and systemic immune responses. Herein, we review the preclinical rationale for combining radiotherapy and immunotherapy, the early clinical trials that have adopted this strategy in breast cancer, and the landscape of ongoing relevant clinical trials. Finally, we propose future directions based on promising preclinical studies that integrate radiation, checkpoint blockade, and novel agents for the treatment of breast cancer.
KW - Cancer immunotherapy
KW - Metastatic breast cancer
KW - Radiation oncology
KW - Triple-negative breast cancer
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85106272337&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106272337&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2021.03.007
DO - 10.1016/j.clbc.2021.03.007
M3 - Article
C2 - 33810972
AN - SCOPUS:85106272337
SN - 1526-8209
VL - 21
SP - 143
EP - 152
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 2
ER -